SEC Form 4 · accession 0001140361-17-033562
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanofi
10% Owner
Period of report
Aug 25, 2017
Accepted (ET)
Aug 29, 2017 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | Aug 25, 2017 | P | 3,684 | $479.1912 | A | 23,811,843 | I | See note |
| Common StockF1,F2,F5,F4 | Aug 25, 2017 | P | 28,586 | $479.9313 | A | 23,840,429 | I | See note |
| Common StockF1,F2,F6,F4 | Aug 25, 2017 | P | 21,360 | $480.7489 | A | 23,861,789 | I | See note |
| Common StockF1,F2,F7,F4 | Aug 25, 2017 | P | 1,302 | $481.6284 | A | 23,863,091 | I | See note |
| Common StockF1,F2,F8,F4 | Aug 25, 2017 | P | 4,485 | $482.8734 | A | 23,867,576 | I | See note |
| Common StockF1,F2,F9,F4 | Aug 25, 2017 | P | 2,000 | $484.21 | A | 23,869,576 | I | See note |
| Common StockF1,F2,F10,F4 | Aug 25, 2017 | P | 5,723 | $485.2798 | A | 23,875,299 | I | See note |
| Common StockF1,F2,F11,F4 | Aug 25, 2017 | P | 2,681 | $485.9939 | A | 23,877,980 | I | See note |
| Common StockF1,F2,F12,F4 | Aug 25, 2017 | P | 2,557 | $487.0108 | A | 23,880,537 | I | See note |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- F10Purchase prices range from $484.86 to $485.85 per share, inclusive.
- F11Purchase prices range from $485.86 to $486.79 per share, inclusive.
- F12Purchase prices range from $486.92 to $487.57 per share, inclusive.
- F2Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
- F3Purchase prices range from $478.42 to $479.39 per share, inclusive.
- F4Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
- F5Purchase prices range from $479.43 to $480.39 per share, inclusive.
- F6Purchase prices range from $480.44 to $481.32 per share, inclusive.
- F7Purchase prices range from $481.47 to $482.09 per share, inclusive.
- F8Purchase prices range from $482.49 to $483.45 per share, inclusive.
- F9Purchase prices range from $483.70 to $484.63 per share, inclusive.
Remarks
Exhibit 24 - Power of Attorney (incorporated herein by reference to Exhibit 24 to Form 4 filed by the Reporting Person with the SEC on February 3, 2016, with respect to Alnylam Pharmaceuticals, Inc.).